| __timestamp | Neurocrine Biosciences, Inc. | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 2917513 |
| Thursday, January 1, 2015 | 32480000 | 7878291 |
| Friday, January 1, 2016 | 68081000 | 8366794 |
| Sunday, January 1, 2017 | 169906000 | 6610381 |
| Monday, January 1, 2018 | 248932000 | 6556000 |
| Tuesday, January 1, 2019 | 354100000 | 6930000 |
| Wednesday, January 1, 2020 | 433300000 | 8758000 |
| Friday, January 1, 2021 | 583300000 | 10806000 |
| Saturday, January 1, 2022 | 752700000 | 9844000 |
| Sunday, January 1, 2023 | 887600000 | 13481000 |
| Monday, January 1, 2024 | 1007200000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Neurocrine's SG&A expenses surged by nearly 4,800%, reflecting its aggressive growth strategy. In contrast, Soleno's expenses grew by approximately 360%, indicating a more conservative approach.
Neurocrine's expenses peaked in 2023, reaching nearly 89 times that of Soleno's, highlighting its expansive operational scale. Meanwhile, Soleno maintained a steady trajectory, with its highest expenses in 2023 still under 2% of Neurocrine's. This disparity underscores the different paths these companies have taken in managing their operational costs. As investors and analysts evaluate these strategies, the question remains: which approach will yield better long-term returns?
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.
Comparing SG&A Expenses: Viatris Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Protagonist Therapeutics, Inc. vs Soleno Therapeutics, Inc. Trends and Insights